Furthermore, inhibiting AXL has significant anti-angiogenic potential which may normalize the tumor vasculature, reduce hypoxia and play a role in reversing ICB resistance[146]; not only does AXL signaling blockade in tumor cells decrease secretion of pro-angiogenic factors, but it also directly impairs vascular endothelial growth factor A-dependent angiogenesis in vessel endothelial cells, which ubiquitously express AXL[165]. This evidence concerns the gene VEGFA and neoplasm.